Login to Your Account

Useless or necessary? Debate rages over sharing of off-label data

By Mari Serebrov
Regulatory Editor

Thursday, November 10, 2016

Debating whether drug and device companies should be able to discuss scientific information about the off-label uses of their products may be an interesting academic exercise for some, but access to that information could be a matter of life or death for patients whose only treatment options are off-label.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription